In recent years, antagonists of NK1, the receptor for SP, have been extensively studied for their ability to relieve pain and pruritus [78,79]; CGRP antagonists have also been widely studied for migraine treatment, including a patch form for transdermal delivery [80]. The gene discussed is TFF2; the disease is migraine disorder.